NSE: ZYDUSLIFE · 7 October 2026
- Zydus Lifesciences Ltd shares moved lower during the session on October 7, 2026, trading down 0.56% to close at ₹1153.00 compared to its previous close of ₹1159.50. The stock opened at ₹1163.30 and fluctuated within a day's range of ₹1149.20 to ₹1167.00.
- Zydus Lifesciences, in partnership with MSN Laboratories, announced the launch of Riociguat Tablets across all five strengths in the United States. The companies are the first to introduce a generic equivalent to Bayer's Adempas, which is indicated for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. According to Bayer's 2025 annual report, global sales of the branded drug were approximately EUR 745 million.
- Trading volume was 0.72 times the 20-day average daily volume.
Why is Zydus Lifesciences share price falling on 7 October 2026?
Zydus Lifesciences Ltd shares moved lower during the session on October 7, 2026, trading down 0.56% to close at ₹1153.00 compared to its previous close of ₹1159.50. The stock opened at ₹1163.30 and fluctuated within a day's range of ₹1149.20 to ₹1167.00.
The broader market witnessed a downward bias, with the Nifty benchmark declining by 0.76%. Sector-wise, the Nifty Pharma index lost 0.43%, reflecting a mild pullback across pharmaceutical peers. Zydus Lifesciences' modest dip of 0.56% aligned closely with the broader healthcare sector's performance, while the stock's 5-day return stood at -3.96% alongside a 20-day return of 0.65%.
Company developments remain centered on recent business updates, including the October 5, 2026 announcement regarding Zydus and MSN Laboratories partnering to launch the first U.S. generic version of Adempas (riociguat tablets), as well as the conclusion of a USFDA inspection at the SEZ II manufacturing plant in Ahmedabad on September 28, 2026, with a single observation and no data integrity issues. While these operational updates provide medium-term context, no single confirmed catalyst was tied directly to today's minor price adjustment.
11.27 lakh shares traded by 7 October 2026 · 03:10 PM IST. This compares with a 20-day average daily volume of 15.55 lakh shares (0.72 times). The five-day average daily volume was 19.41 lakh shares. Separately, the NSE report for 6 October 2026 showed 8.41 lakh shares delivered, representing 53.40% of that day’s traded volume. The same report recorded 30,967 trades.
The stock moved down 0.56% in a session where the Nifty and Nifty Pharma indices also drifted lower. With volume below its 20-day average and no same-day catalyst announced, the price action reflects routine market consolidation following recent sessions.
Latest Company Developments
Zydus Lifesciences, in partnership with MSN Laboratories, announced the launch of Riociguat Tablets across all five strengths in the United States. The companies are the first to introduce a generic equivalent to Bayer's Adempas, which is indicated for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. According to Bayer's 2025 annual report, global sales of the branded drug were approximately EUR 745 million.
Establishes a first-to-market position in a complex specialty generic category with meaningful global brand sales.
The USFDA concluded a cGMP inspection at the company's manufacturing facility located at SEZ II in Ahmedabad between September 21 and September 28, 2026. The inspection closed with a single observation and zero data integrity related observations. The company stated it will work closely with the agency to address the observation expeditiously.
Maintains regulatory compliance clarity for a key manufacturing site contributing to export operations.
CRISIL Ratings reviewed and reaffirmed Zydus Lifesciences' various long-term bank facilities of ₹4,724 crore at CRISIL AAA/Stable and short-term ratings at CRISIL A1+. Commercial papers and non-convertible debentures also retained their top-tier ratings, though there were no outstanding instruments of those types as of the review date.
Reflects strong financial stability and high creditworthiness across the company's debt instruments.
a press release dated October 05, 2026, titled "Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.".
a press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 5.12% on 30 June 2026. This compares with 4.92% on 18 June 2026, a change of +0.20 percentage points.
The filing reported 38 MF/UTI holders.
Research & Brokerage Views
Maintained an Outperform rating, highlighting new business buildout and specialty pipeline execution as key growth drivers.
Raised target price following earnings updates but retained a Sell rating on valuation concerns.
What to Watch Next
- Execution and initial sales traction from the newly launched generic riociguat tablets in the U.S. market
- Company response and formal resolution timeline regarding the single USFDA observation at the Ahmedabad SEZ II plant
- Progress on the 50:50 joint venture closing with Sunshine Healthcare Lanka expected by December 2026
- Cash delivery volumes relative to the 20-day average of 1,126,997 shares traded during the session
Other Dated Coverage
- Why Zydus Life Shares Are Rising 1.80% Today | 6 October 2026 — 6 October 2026
- Why Zydus Lifesciences Shares Fell 2.46% Today: Market Context | 1 October 2026 — 1 October 2026
- Why Zydus Lifesciences Shares Fell 3.21% Today: Sector Weakness | 30 September 2026 — 30 September 2026
More Zydus Lifesciences news and dated analysis →
Frequently Asked Questions
What is the latest Zydus Lifesciences company news?
Zydus Lifesciences, in partnership with MSN Laboratories, announced the launch of Riociguat Tablets across all five strengths in the United States. The companies are the first to introduce a generic equivalent to Bayer's Adempas, which is indicated for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. According to Bayer's 2025 annual report, global sales of the branded drug were approximately EUR 745 million.
How strong was Zydus Lifesciences’s trading volume?
11.27 lakh shares traded, 0.72 times the 20-day average daily volume. The price and volume data are dated 7 October 2026 · 03:10 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.